Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACST

Acasti Pharma (ACST) Stock Price, News & Analysis

Acasti Pharma logo

About Acasti Pharma Stock (NASDAQ:ACST)

Advanced Chart

Key Stats

Today's Range
$3.03
$3.14
50-Day Range
$2.56
$3.60
52-Week Range
$1.98
$3.60
Volume
12,261 shs
Average Volume
22,722 shs
Market Capitalization
$29.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Stock News Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)
See More Headlines

ACST Stock Analysis - Frequently Asked Questions

Acasti Pharma Inc. (NASDAQ:ACST) posted its earnings results on Friday, June, 21st. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.30.

Acasti Pharma's stock reverse split on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
6/21/2024
Today
5/30/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACST
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+221.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.57 per share
Price / Book
0.47

Miscellaneous

Free Float
8,770,000
Market Cap
$29.23 million
Optionable
Not Optionable
Beta
1.52
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ACST) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners